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Purpose of the study
The new LPV/r tablet formulation has significant patient
benefits over the old LPV/r SGC, including a lack of food/
fluid restrictions, no need for refrigeration and a reduced
daily pill count. However, like many antiretroviral drugs,
the pharmacokinetics of the new LPV/r tablet during preg-
nancy is poorly understood. Here we report total and
unbound LPV plasma concentrations during pregnancy
and at post-partum.
Methods
In this prospective, open-labelled study, pregnant HIV-
positive patients received the LPV/r tablet formulation as
part of their routine pre-natal care. Demographic and clin-
ical data were collected and LPV plasma (total) and ultra-
filtrate (unbound) concentrations were determined in the
first (T1) and/or second (T2) and/or third (T3) trimester
using HPLC-MS/MS. Post-partum (PP) sampling was per-
formed where applicable. Ante-partum and post-partum
PK parameters were compared using a one-way ANOVA
(for independent data sets) and a paired t-test (for paired
data).
Summary of results
From January 2007, 33 women were enrolled in the study;
31/33 received LPV/r tablet at the standard dose of 2 tab-
lets BID. The remaining two patients were prescribed 4
tablets OD and 3 tablets BID, respectively. 30/33 women
initiated LPV/r treatment during pregnancy. Median gesta-
tion at initiation was 25 weeks. 3/33 women were receiv-
ing HAART prior to pregnancy. Median baseline CD4
count was 349 (14–836). Median baseline viral load was
9,100 copies/ml (<50–267,408).
LPV/r (total and unbound) concentrations were deter-
mined in 1/33 (T1); 10/33 (T2); 29/33 (T3) and 8/33
(PP) (≤12 weeks) patients. 2/10 patients at T2 and 3/29
patients at T3 fell below the recommended LPV MEC
(<1000 ng/ml), respectively. Median total LPV concentra-
tions at T2 and T3 were 2770 ng/ml (1759–4202) and
3371 ng/ml (2331–4310), respectively; and were signifi-
cantly lower relative to LPV concentrations observed at PP
[5352 ng/ml (2667–7293)] (p = 0.042). Equally, in a
paired analysis of eight patients (T3 vs. PP), total LPV con-
centrations were significantly reduced at T3 vs. PP (p =
0.021). However, no significant difference was observed
in the % unbound LPV at T3 [0.93% (0.71–1.10)] vs. PP
[0.96% (0.81–1.19)].
Conclusion
Standard dosage of LPV/r during pregnancy resulted in
adequate therapeutic drug levels in the majority women
examined. In addition, the similarities in the percentage
of unbound LPV in the third trimester versus post-partum
suggest that the standard dose of LPV/r is appropriate dur-
ing pregnancy. Further research into this is required.
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